Document is current
Any future updates will be listed below
-
Authors
Fuentes, Mary Esmeralda
Lu, Xiaoyin
Flores, Natasha M.
Hausmann, Simone
Mazur, Pawel K.
-
Funding
Funding for this research was provided by:
National Institutes of Health (R01CA236118, R01CA278940, R01CA272844, R01CA236949, R01CA266280, R01CA272843)
National Institutes of Health (K99CA255936)
Neuroendocrine Tumor Research Foundation (NETRF-Mazur)
U.S. Department of Defense (CA181486)
Cancer Prevention and Research Institute of Texas (RP220391 and RR160078)
Cancer Prevention and Research Institute of Texas (RP210028)
Cancer Prevention and Research Institute of Texas (RP210028)
American Cancer Society (Postdoctoral Fellowship)
- License Information
-
More Information
Article History
Received: 17 November 2023
Accepted: 3 April 2024
First Online: 12 April 2024
Competing interests
: P.K.M. is a co-scientific founder, consultant, and stockholder of Amplified Medicines, Inc.; consultant and stockholder of Ikena Oncology, Inc. and Alternative Bio, Inc. The other authors declare no competing interests.
